Please login to the form below

Not currently logged in
Email:
Password:

raltegravir

This page shows the latest raltegravir news and features for those working in and with pharma, biotech and healthcare.

Antibiotics among 7 new drugs backed by EMA

Antibiotics among 7 new drugs backed by EMA

Other new drugs backed by the CHMP include Merck &Co's Dutrebis (lamivudine/raltegravir), another addition to the growing list of combination regimens for HIV.

Latest news

  • A new option for people with HIV A new option for people with HIV

    Other integrase inhibitors. Raltegravir ( Isentress; Merck) was the first integrase inhibitor to be approved by the US FDA in October 2007. ... Raltegravir has since been launched in several countries worldwide for use in combination with other

  • FDA clears Isentress formulation for infants with HIV FDA clears Isentress formulation for infants with HIV

    The approval covers the use of this Isentress (raltegravir) formulation in children as young as four weeks of age who weigh at least 3kg.

  • ViiV's Tivicay for HIV on course for EU approval ViiV's Tivicay for HIV on course for EU approval

    Tivicay is the third entrant in the integrase inhibitor class after Merck &Co's Isentress (raltegravir) - which was first approved in 2007 - and Gilead Sciences' elvitegravir which was approved last year

  • ViiV gets US nod for HIV drug dolutegravir ViiV gets US nod for HIV drug dolutegravir

    a twice-daily treatment with rival integrase inhibitor Isentress (raltegravir) from Merck &Co and found they were equivalent in previously-untreated HIV patients.

  • Merck profit slides as generics continue to bite Merck profit slides as generics continue to bite

    HIV drug Isentress (raltegravir) climbed 5 per cent to $410m, holding up fairly well despite increased competition from the likes of Gilead Sciences' elvitegravir, while sales of cholesterol drugs Zetia (ezetimibe)

More from news
Approximately 1 fully matching, plus 35 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics